Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Subconjunctival injection of low-molecular-weight heparin-taurocholate 7 inhibits corneal neovascularization.

Yoon SY, Kim JY, Kim ES, Kim SY, Kim MJ, Tchah H.

Cornea. 2013 Nov;32(11):1488-92. doi: 10.1097/ICO.0b013e3182a48009.

PMID:
24055905
2.

Comparison of Topical Low-Molecular-Weight Heparin-Taurocholate and Bevacizumab for Treatment and Prevention of Corneal Neovascularization.

Moon CH, Moon BG, Kim JY, Kim MJ, Tchah H.

Cornea. 2017 Apr;36(4):497-501. doi: 10.1097/ICO.0000000000001105.

PMID:
27941385
3.

Attenuation of corneal neovascularization by topical low-molecular-weight heparin-taurocholate 7 without bleeding complication.

Kim JY, Kim SY, Cheon MH, Kim ES, Song IS, Kim MJ, Tchah H.

Int J Ophthalmol. 2016 Sep 18;9(9):1255-9. doi: 10.18240/ijo.2016.09.03. eCollection 2016.

4.

Prevention and treatment of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with corticosteroid in experimental rats.

Hashemian MN, Moghimi S, Kiumehr S, Riazi M, Amoli FA.

Ophthalmic Res. 2009;42(2):90-5. doi: 10.1159/000224783. Epub 2009 Jun 18.

PMID:
19546599
5.

Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats.

Hashemian MN, Z-Mehrjardi H, Moghimi S, Tahvildari M, Mojazi-Amiri H.

Ophthalmic Res. 2011;46(1):50-4. doi: 10.1159/000322061. Epub 2011 Jan 6.

PMID:
21212709
6.

Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.

Öner V, Küçükerdönmez C, Akova YA, Çolak A, Karalezli A.

Ophthalmic Res. 2012;48(3):118-23. doi: 10.1159/000337139. Epub 2012 Apr 24.

PMID:
22538642
7.

Inhibition of experimental angiogenesis of cornea by various doses of doxycycline and combination of triamcinolone acetonide with low-molecular-weight heparin and doxycycline.

Aydin E, Kivilcim M, Peyman GA, Esfahani MR, Kazi AA, Sanders DR.

Cornea. 2008 May;27(4):446-53. doi: 10.1097/ICO.0b013e3181605ff9.

PMID:
18434849
8.

Effect of subconjunctival bevacizumab (Avastin) on experimental corneal neovascularization in guinea pigs.

Hurmeric V, Mumcuoglu T, Erdurman C, Kurt B, Dagli O, Durukan AH.

Cornea. 2008 Apr;27(3):357-62. doi: 10.1097/ICO.0b013e318160d019.

PMID:
18362668
9.

Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model.

Papathanassiou M, Theodossiadis PG, Liarakos VS, Rouvas A, Giamarellos-Bourboulis EJ, Vergados IA.

Am J Ophthalmol. 2008 Mar;145(3):424-431. doi: 10.1016/j.ajo.2007.11.003. Epub 2008 Jan 22.

PMID:
18207123
10.

Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.

Avisar I, Weinberger D, Kremer I.

Curr Eye Res. 2010 Feb;35(2):108-15. doi: 10.3109/02713680903429007.

PMID:
20136420
11.

Effects of subconjunctivally injected bevacizumab, etanercept, and the combination of both drugs on experimental corneal neovascularization.

Ozdemir O, Altintas O, Altintas L, Yildiz DK, Sener E, Caglar Y.

Can J Ophthalmol. 2013 Apr;48(2):115-20. doi: 10.1016/j.jcjo.2012.12.003.

PMID:
23561605
12.

Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization.

Ozdemir O, Altintas O, Altintas L, Ozkan B, Akdag C, Yüksel N.

Arq Bras Oftalmol. 2014 Aug;77(4):209-13.

13.

Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin).

Kim TI, Kim SW, Kim S, Kim T, Kim EK.

Cornea. 2008 Apr;27(3):349-52. doi: 10.1097/ICO.0b013e31815cf67d.

PMID:
18362666
14.

The effect of subconjunctival suramin on corneal neovascularization in rabbits.

Lee HS, Chung SK.

Cornea. 2010 Jan;29(1):86-92. doi: 10.1097/ICO.0b013e3181ae91e3.

PMID:
19907290
15.

Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.

Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR.

Invest Ophthalmol Vis Sci. 2009 Apr;50(4):1659-65. doi: 10.1167/iovs.08-1997. Epub 2008 Nov 7.

PMID:
18997093
16.

Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial.

Petsoglou C, Balaggan KS, Dart JK, Bunce C, Xing W, Ali RR, Tuft SJ.

Br J Ophthalmol. 2013 Jan;97(1):28-32. doi: 10.1136/bjophthalmol-2012-302137. Epub 2012 Oct 20.

PMID:
23087419
17.

The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model.

Sener E, Yuksel N, Yildiz DK, Yilmaz B, Ozdemir O, Caglar Y, Degirmenci E.

Curr Eye Res. 2011 Nov;36(11):1005-13. doi: 10.3109/02713683.2011.601840.

PMID:
21999227
18.

Safety studies on intravenous infusion of a potent angiogenesis inhibitor: taurocholate-conjugated low molecular weight heparin derivative LHT7 in preclinical models.

Alam F, Hwang SR, Al-Hilal TA, Chung SW, Kim HS, Kang BH, Zhang HS, Shin SH, Lee JY, Kang MS, Kwon GH, Jeon OC, Kim SY, Byun Y.

Drug Dev Ind Pharm. 2016 Aug;42(8):1247-57. doi: 10.3109/03639045.2015.1122609. Epub 2015 Dec 14.

PMID:
26612099
19.

Comparative study of ranibizumab and bevacizumab on corneal neovascularization in rabbits.

Kim EK, Kong SJ, Chung SK.

Cornea. 2014 Jan;33(1):60-4. doi: 10.1097/ICO.0000000000000007.

PMID:
24240485
20.

Topically administered bevacizumab had longer standing anti-angiogenic effect than subconjunctivally injected bevacizumab in rat corneal neovacularization.

Kim J, Kim D, Kim ES, Kim MJ, Tchah H.

Int J Ophthalmol. 2013 Oct 18;6(5):588-91. doi: 10.3980/j.issn.2222-3959.2013.05.06. eCollection 2013.

Supplemental Content

Support Center